Discontinued — last reported Q4 '22
Products & Services · Expense incurred by the collaboration
Aducanumab — Expense incurred by the collaboration
Biogen Aducanumab — Expense incurred by the collaboration remained flat by 0.0% to $37.35M in Q4 2022 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2016
Last reportedQ4 2022Feb 14, 2024
How to read this metric
An increase suggests higher investment in development or commercialization activities, while a decrease may indicate reduced activity, project wind-downs, or improved operational efficiencies within the partnership.
Detailed definition
This metric represents the total gross costs and operational expenditures associated with a specific pharmaceutical prod...
Peer comparison
Comparable to R&D or SG&A cost-sharing figures reported by other biopharmaceutical companies in joint development agreements.
Metric ID:
biib_segment_aducanumab_expense_incurred_by_the_collaborationHistorical Data
4 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | |
|---|---|---|---|---|
| Value | $37.35M | $37.35M | $37.35M | $37.35M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% |
Range$37.35M – $37.35M
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aducanumab — expense incurred by the collaboration?
- Biogen (BIIB) reported aducanumab — expense incurred by the collaboration of $37.35M in Q4 2022.
- What does aducanumab — expense incurred by the collaboration mean?
- The total gross costs incurred by a joint venture or partnership for a specific drug product.